What does this research mean for the field?

Real-world utilization of comprehensive genomic profiling after resection for stage I-III non-small cell lung cancer has increased substantially over time and is largely concordant with clinical guidelines. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

This research aims to evaluate the real-world adoption trends of comprehensive genomic profiling in resected stage I–III non-small cell lung cancer.

May 29, 2026Journal of Clinical Oncology

Real-world adoption of comprehensive genomic profiling in a national cohort of patients with resected stage I–III non–small cell lung cancer.

View Full Paper

Ask AI

Bookmark

Authors

BHBrendan HeidenWashington University in St. Louis DEDaniel B. EatonSt. Louis VA Medical Center AKArvind KumarWashington University in St. Louis

Discussion

Member takes

Implication

Retrospective cohort analysis shows CGP uptake increased in patients with resected NSCLC, indicating evolving clinical practices.

Key Points

This research aims to evaluate the real-world adoption trends of comprehensive genomic profiling in resected stage I–III non-small cell lung cancer.
Retrospective cohort study of 6,605 patients with resected pathologic stage I–III NSCLC from 2019 to 2025.
Assessment of CGP defined as next-generation sequencing of the primary tumor within 3 months post-surgery.
Multivariable logistic regression to determine factors associated with CGP uptake.
CGP testing was performed on 1,337 (20.2%) patients, increasing from 11.4% in 2019 to 25.8% in 2025.
In 2025, CGP utilization among stage Ib-III NSCLC patients reached 54.9%.
Key genomic alterations identified included KRAS G12C (10.62%) and EGFR mutations (total 3.59%).

Cite This Study

Heiden et al. (2026) studied this question.

synapsesocial.com/papers/6a192d2efab5b468c4416014 https://doi.org/10.1200/jco.2026.44.16_suppl.8043

View Full Paper

Ask AI

Bookmark

Real-world adoption of comprehensive genomic profiling in a national cohort of patients with resected stage I–III non–small cell lung cancer.

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world adoption of comprehensive genomic profiling in a national cohort of patients with resected stage I–III non–small cell lung cancer.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider